Prophylactic Riserodrenate for Patients With Peripheral Lung Tumors Treated With SBRT
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This is a double blind randomized controlled study investigating the efficacy of a single
dose of 150 mg risedronate (a bone anti-resorptive) vs a single dose of placebo given prior
to SBRT for peripheral lung tumors that are within 2 cm of the chest wall. Our hypothesis is
that the use of a single dose of 150 mg risedronate will eliminate or greatly reduce the
rapid bone loss that occurs with radiation induced early osteoclast recruitment/activation.
Patients will be given either a single dose of 150 mg risedronate or placebo at the time of
their treatment mapping "simulation" CT scan. Typically, radiation treatments begin at 1 - 3
weeks following this mapping scan, as each treatment plan requires detailed physics
calculations and quality assurance checks.
All CT imaging referenced below is performed as a routine standard of care surveillance and
is necessary for cancer treatment follow-up. These chest CT scans that are utilized in this
research protocol would be performed every 3 months regardless of inclusion on this trial.